Pulmonary Hypertension

Global Pulmonary Hypertension Disease Insights and Market Forecasts to 2026: Uptravi, Opsumit, Tyvaso, Adempas, LIQ861, Sotatercept, Orenitram - ResearchAndMarkets.com - Yahoo Finance Global Pulmonary Hypertension Disease Insights and Market Forecasts to 2026: Uptravi, Opsumit, Tyvaso, Adempas, LIQ861, Sotatercept, Orenitram - ResearchAndMarkets.com - Yahoo Finance Posted: 16 Dec 2020 12:00 AM PST The "Pulmonary Hypertension - Disease Insights and Market Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering. "Pulmonary hypertension: Disease Insights and Market Forecasts to 2026" report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Pulmonary hypertension disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for Pulmonary hypertension, drug wise in $ sales and patient numbers at glo...

Adempas Safe in PAH Patients Over Long Term, Real-world Study Shows - Pulmonary Hypertension News Adempas Safe in PAH Patients Over Long Term, Real-world Study Shows - Pulmonary Hypertension News Posted: 07 Dec 2020 12:00 AM PST Long-term treatment with Bayer 's  Adempas ( riociguat ) was safe and well-tolerated in people with pulmonary arterial hypertension (PAH), according to data from the real-world EXPERT study. These findings from clinical practice were consistent with those reported in previous clinical trials, supporting the therapy's favorable safety profile. Data from EXPERT was reported in an article, " Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry ," published in the journal Respiratory Medicine . Designed to widen lung blood vessels and reduce blood pressure, Adempas is approved for the treatment of adults with PAH and ino...

Gil Hospital professor releases pulmonary hypertension gene's traits - Korea Biomedical Review Gil Hospital professor releases pulmonary hypertension gene's traits - Korea Biomedical Review Posted: 01 Dec 2020 12:00 AM PST Patients with pulmonary hypertension (PH) accompanied by BMPR-2 gene mutation tend to experience more severe and fast-progressing symptoms and receive treatments at an earlier age, a local researcher said Tuesday. PH is a fatal disease that causes blood circulation to deteriorate from increased blood pressure in the pulmonary artery, which supplies blood from the heart to the lungs. PH patients eventually die due to right heart failure or sudden cardiac death. Professor Jung Wook-jin of the Department of Cardiology at Gachon University Gil Hospital and his team have found that pulmonary hypertension (PH) patients with BMPR-2 gene mutation experience more severe symptoms at an earlier age. (Gil Hospital) P...

SoniVie Receives FDA Breakthrough Device Designation for the TIVUS System for Renal Artery Denervation - Vascular Disease Management SoniVie Receives FDA Breakthrough Device Designation for the TIVUS System for Renal Artery Denervation - Vascular Disease Management Posted: 09 Dec 2020 12:00 AM PST  SoniVie Acquires New Intellectual Property and Other Assets from Cardiosonic Moving TIVUS into New Therapeutic Areas Beyond Pulmonary Hypertension TEL AVIV, Israel, Dec. 09, 2020 (GLOBE NEWSWIRE) -- SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound (TIVUS) System to treat a variety of hypertensive disorders, today announced that it has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the TIVUS System for renal artery denervation for the treatment of resistant hypertension, which is defined as blood pressure that remains above 140/90 mmHg despite use of ...

Drug for pulmonary hypertension may become an option against cancer - EurekAlert Drug for pulmonary hypertension may become an option against cancer - EurekAlert Posted: 15 Dec 2020 08:16 AM PST By André Julião  |  Agência FAPESP - A drug used to treat pulmonary hypertension significantly reduced the capacity of tumor cells to migrate and invade other tissues in trials involving pancreatic, ovarian, breast cancer, and leukemia cell lines. Furthermore, in mice with an aggressive form of breast cancer, the drug reduced the incidence of metastasis in the liver and lungs by 47% and lengthened survival compared with untreated animals. The study is published  in Scientific Reports . "The drug ambrisentan is an inhibitor of the endothelin type A receptor, which is known to play a role in vasoconstriction, so the drug is used to treat pulmonary hypertension [ typically caused by autoimmune diseases such as lupus and systemic sclerosis ]. I...

Researcher creates first national registry for pulmonary hypertension - UCalgary News Researcher creates first national registry for pulmonary hypertension - UCalgary News Posted: 07 Dec 2020 12:00 AM PST Pulmonary hypertension (PH) is a serious condition that causes blocked arteries in the lungs, often leading to heart failure. Patients with PH often suffer with shortness of breath, leg swelling and fainting. Despite treatment options, including lung transplants, many PH patients become sicker and ultimately die from their disease. Kathy Downey, 52, was diagnosed with PH in March 2020, five years after she started seeking answers for her symptoms. "It started with shortness of breath and exhaustion," says Downey. "Over time it became harder to walk even short distances. Even doing the laundry became a difficult task." When the mom of young adult children started developing numbness in her arms in February 2020, she w...

Pulmonary Hypertension With ILD: Diagnostic and Treatment Challenges - Pulmonology Advisor Pulmonary Hypertension With ILD: Diagnostic and Treatment Challenges - Pulmonology Advisor Posted: 14 Jul 2020 12:00 AM PDT Although pulmonary hypertension as a result of interstitial lung disease (PH-ILD) is commonly encountered in clinical practice and linked to significant morbidity and mortality, there is no consensus regarding screening or management of the disease. A recent review published in CHEST details the challenges involved in the diagnosis and treatment of PH-ILD. 1 "We have the tools we need to make a diagnosis of PH in ILD. However, it is often difficult to determine what contributes more to patients' symptomatology — underlying ILD or superimposed PH," according to coauthor Oksana A. Shlobin, MD, FCCP, medical director of the Pulmonary Hypertension Program and director of education for the Advanced Lung Disease and Tra...

DNA methyltransferase 3B deficiency unveils a new pathological mechanism of pulmonary hypertension - Science Advances DNA methyltransferase 3B deficiency unveils a new pathological mechanism of pulmonary hypertension - Science Advances Posted: 09 Dec 2020 12:00 AM PST Abstract DNA methylation plays critical roles in vascular pathology of pulmonary hypertension (PH). The underlying mechanism, however, remains undetermined. Here, we demonstrate that global DNA methylation was elevated in the lungs of PH rat models after monocrotaline administration or hypobaric hypoxia exposure. We showed that DNA methyltransferase 3B (DNMT3B) was up-regulated in both PH patients and rodent models. Furthermore, Dnmt3b −/− rats exhibited more severe pulmonary vascular remodeling. Consistently, inhibition of DNMT3B promoted proliferation/migration of pulmonary artery smooth muscle cells (PASMCs) in response to platelet-derived growth factor–BB (PDGF-BB). In c...